Monoclonal Antibody Combo Reduces Symptomatic COVID-19 Infection Risk by 83%

Retrieved on: 2022-04-21 20:39:27

Tags for this article:

Clinical trials

Health

COVID-19 vaccination in the United States

RNA vaccines

Adenoviridae

Medical research

Oxford–AstraZeneca COVID-19 vaccine

COVID-19 vaccine

AstraZeneca

The New England Journal of Medicine

COVID-19 vaccine clinical research

COVID-19 vaccination in Canada

Click the tags to see associated articles and topics

Monoclonal Antibody Combo Reduces Symptomatic COVID-19 Infection Risk by 83%. View article details on hiswai:

Excerpt

Delaware-based AstraZeneca US announced its Evusheld monoclonal antibody (mAbs) combination reduced the risk of developing symptomatic COVID-19 by ...

Article found on: www.precisionvaccinations.com

View Original Article